Author + information
- Published online March 15, 2011.
- L. Samuel Wann, MD, MACC, FAHA, Chair, 2011 Writing Group Member⁎,
- Anne B. Curtis, MD, FACC, FAHA, 2011 Writing Group Member⁎,
- Kenneth A. Ellenbogen, MD, FACC, FHRS, 2011 Writing Group Member†,
- N.A. Mark Estes III, MD, FACC, FHRS, 2011 Writing Group Member‡,§,
- Michael D. Ezekowitz, MB, ChB, FACC, 2011 Writing Group Member⁎,§,
- Warren M. Jackman, MD, FACC, FHRS, 2011 Writing Group Member⁎,
- Craig T. January, MD, PhD, FACC, 2011 Writing Group Member⁎,
- James E. Lowe, MD, FACC, 2011 Writing Group Member⁎,
- Richard L. Page, MD, FACC, FHRS, FAHA, 2011 Writing Group Member†,
- David J. Slotwiner, MD, FACC, 2011 Writing Group Member†,§,
- William G. Stevenson, MD, FACC, FAHA, 2011 Writing Group Member∥ and
- Cynthia M. Tracy, MD, FACC, 2011 Writing Group Member⁎
2006 Writing Committee Members
Valentin Fuster, MD, PhD, FACC, FAHA, FESC, Co-Chair; Lars E. Rydén, MD, PhD, FACC, FESC, FAHA, Co-Chair; David S. Cannom, MD, FACC; Harry J. Crijns, MD, FACC, FESC; Anne B. Curtis, MD, FACC, FAHA; Kenneth A. Ellenbogen, MD, FACC, FHRS† Jonathan L. Halperin, MD, FACC, FAHA; G. Neal Kay, MD, FACC; Jean-Yves Le Heuzey, MD, FESC; James E. Lowe, MD, FACC; S. Bertil Olsson, MD, PhD, FESC; Eric N. Prystowsky, MD, FACC; Juan Luis Tamargo, MD, FESC; L. Samuel Wann, MD, MACC, FAHA, FESC
ACCF/AHA Task Force Members
Alice K. Jacobs, MD, FACC, FAHA, Chair; Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect; Nancy Albert, PhD, CCNS, CCRN, FAHA; Mark A. Creager, MD, FACC, FAHA; Steven M. Ettinger, MD, FACC; Robert A. Guyton, MD, FACC; Jonathan L. Halperin, MD, FACC, FAHA; Judith S. Hochman, MD, FACC, FAHA; Frederick G. Kushner, MD, FACC, FAHA; Erik Magnus Ohman, MD, FACC; William G. Stevenson, MD, FACC, FAHA; Clyde W. Yancy, MD, FACC, FAHA
Table of Contents
1.1 Methodology and Evidence Review......1333
1.2 Organization of the Writing Committee......1333
1.3 Document Review and Approval......1333
184.108.40.206.5 Recommendation for Use of Oral Direct Thrombin Inhibitor Anticoagulant Agents......1333
Appendix 1. Author Relationships With Industry and Other Entities......1336
Appendix 2. Reviewer Relationships With Industry and Other Entities......1337
A primary challenge in the development of clinical practice guidelines is keeping pace with the stream of new data on which recommendations are based. In an effort to respond promptly to new evidence, the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force on Practice Guidelines (Task Force) has created a “focused update” process to revise the existing guideline recommendations that are affected by the evolving data or opinion. Before the initiation of this focused approach, periodic updates and revisions of existing guidelines required up to 3 years to complete. Now, however, new evidence will be reviewed in an ongoing fashion to more efficiently respond to important science and treatment trends that could have a major impact on patient outcomes and quality of care. Evidence will be reviewed at least twice a year, and updates will be initiated on an as-needed basis and completed as quickly as possible while maintaining the rigorous methodology that the ACCF and AHA have developed during their partnership of more than 20 years.
These updated guideline recommendations reflect a consensus of expert opinion after a thorough review primarily of late-breaking clinical trials identified through a broad-based vetting process as being important to the relevant patient population, as well as other new data deemed to have an impact on patient care (see Section 1.1, Methodology and Evidence Review, for details). This focused update is not intended to represent an update based on a full literature review from the date of the previous guideline publication. Specific criteria/considerations for inclusion of new data include the following:
• publication in a peer-reviewed journal;
• large, randomized, placebo-controlled trial(s);
• nonrandomized data deemed important on the basis of results affecting current safety and efficacy assumptions;
• strength/weakness of research methodology and findings;
• likelihood of additional studies influencing current findings;
• impact on current and/or likelihood of need to develop new performance measure(s);
• request(s) and requirement(s) for review and update from the practice community, key stakeholders, and other sources free of relationships with industry or other potential bias;
• number of previous trials showing consistent results; and
• need for consistency with a new guideline or guideline revisions.
In analyzing the data and developing the recommendations and supporting text, the focused update writing group used evidence-based methodologies developed by the Task Force that are described elsewhere (1). The committee reviewed and ranked evidence supporting current recommendations with the weight of evidence ranked as Level A if the data were derived from multiple randomized clinical trials or meta-analyses. The committee ranked available evidence as Level B when data were derived from a single randomized trial or nonrandomized studies. Evidence was ranked as Level C when the primary source of the recommendation was consensus opinion, case studies, or standard of care. In the narrative portions of these guidelines, evidence is generally presented in chronological order of development. Studies are identified as observational, retrospective, prospective, or randomized when appropriate. For certain conditions for which inadequate data are available, recommendations are based on expert consensus and clinical experience and ranked as Level C. An example is the use of penicillin for pneumococcal pneumonia, for which there are no randomized trials and treatment is based on clinical experience. When recommendations at Level C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues where sparse data are available, a survey of current practice among the clinicians on the writing committee was the basis for Level C recommendations and no references are cited. The schema for Classification of Recommendations (COR) and Level of Evidence (LOE) is summarized in Table 1, which also illustrates how the grading system provides an estimate of the size and the certainty of the treatment effect. A new addition to the ACCF/AHA methodology is a separation of the Class III recommendations to delineate whether the recommendation is determined to be of “no benefit” or associated with “harm” to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment/strategy with respect to another for COR I and IIa, LOE A or B only have been added.
The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of relationships with industry and other entities (RWI) among the writing group. Specifically, all members of the writing group, as well as peer reviewers of the document, are asked to disclose all current relationships and those existing 12 months before initiation of the writing effort. In response to implementation of a newly revised RWI policy approved by the ACC and AHA, it is also required that the writing group chair plus a majority of the writing group (50%) have no relevant RWI. All guideline recommendations require a confidential vote by the writing group and must be approved by a consensus of the members voting. Members who were recused from voting are noted on the title page of this document and in Appendix 1. Members must recuse themselves from voting on any recommendation to which their RWI apply. Any writing group member who develops a new RWI during his or her tenure is required to notify guideline staff in writing. These statements are reviewed by the Task Force on Practice Guidelines and all members during each conference call and/or meeting of the writing group and are updated as changes occur. For detailed information about guideline policies and procedures, please refer to the ACCF/AHA methodology and policies manual (1). Authors' and peer reviewers' RWI pertinent to this guideline are disclosed in Appendixes 1 and 2, respectively. In addition, to ensure complete transparency, writing group members' comprehensive disclosure information—including RWI not pertinent to this document—is available online as a supplement to this document. Disclosure information for the Task Force is also available online at www.cardiosource.org/ACC/About-ACC/Leadership/Guidelines-and-Documents-Task-Forces.aspx. The work of the writing group was supported exclusively by the ACCF and AHA and Heart Rhythm Society (HRS) without commercial support. Writing group members volunteered their time for this effort.
The ACCF/AHA practice guidelines address patient populations (and healthcare providers) residing in North America. As such, drugs that are currently unavailable in North America are discussed in the text without a specific classification of recommendation. For studies performed in large numbers of subjects outside of North America, each writing group reviews the potential impact of different practice patterns and patient populations on the treatment effect and the relevance to the ACCF/AHA target population to determine whether the findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, and prevention of specific diseases or conditions. These practice guidelines represent a consensus of expert opinion after a thorough and systematic review of the available current scientific evidence and are intended to improve patient care. The guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and patient in light of all the circumstances presented by that patient. Thus, there are circumstances in which deviations from these guidelines may be appropriate. Clinical decision making should consider the quality and availability of expertise in the area where care is provided. When these guidelines are used as the basis for regulatory or payer decisions, the goal should be improvement in quality of care. The Task Force recognizes that situations arise for which additional data are needed to better inform patient care; these areas will be identified within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these recommendations are effective only if they are followed. Because lack of patient understanding and adherence may adversely affect outcomes, physicians and other healthcare providers should make every effort to engage the patient's active participation in prescribed medical regimens and lifestyles.
The recommendations in this focused update will be considered current until they are superseded by another focused update or the full-text guideline is revised. This focused update is published in the Journal of the American College of Cardiology, Circulation, and HeartRhythm as an update to the full-text guideline, and it is also available on the ACC (www.cardiosource.org), AHA (my.americanheart.org), and HRS (www.hrsonline.org) World Wide Web sites. A revised version of the full-text guideline with links to the focused update is e-published in the March 15, 2011, issues of the Journal of the American College of Cardiology and Circulation. For easy reference, this online-only version denotes sections that have been updated.
Alice K. Jacobs, MD, FACC, FAHA Chair, ACCF/AHA Task Force on Practice Guidelines
1.1 Methodology and Evidence Review
The publication of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial was considered important enough to prompt a focused update of the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation (2). To provide clinicians with a comprehensive set of data, whenever deemed appropriate or when published, the absolute risk difference and number needed to treat or harm will be provided in the guideline, along with confidence intervals (CI) and data related to the relative treatment effects such as odds ratio, relative risk (RR), hazard ratio, or incidence rate ratio.
Consult the full-text version or executive summary of the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation for policy on clinical areas not covered by the focused update (2). The individual recommendations in this focused update will be incorporated into future revisions and/or updates of the full-text guideline.
1.2 Organization of the Writing Committee
For this focused update, all eligible members of the 2006 Atrial Fibrillation Writing Committee were invited to participate; those who agreed (referred to as the 2011 Focused Update Writing Group) were required to disclose all RWI relevant to the data under consideration. The HRS was invited to be a partner on this update and provided 3 representatives.
1.3 Document Review and Approval
This document was reviewed by 2 official reviewers each nominated by the ACCF, the AHA, and the HRS, and 5 individual content reviewers (including members of the ACCF Electrophysiology Committee, the Atrial Fibrillation Performance Measures Committee, and the Atrial Fibrillation Data Standards Committee). All information on reviewers' RWI was collected and distributed to the writing committee and is published in this report (Appendix 2).
This document was approved for publication by the governing bodies of the ACCF, AHA, and HRS.
This guideline update focuses on the use of dabigatran, a new antithrombotic agent that was recently approved by the US Food and Drug Administration (FDA), for the management of patients with atrial fibrillation (AF).
220.127.116.11.5 Recommendation for Use of Oral Direct Thrombin Inhibitor Anticoagulant Agents
(See Table 2).
Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin (factor IIa) inhibitor dabigatran. This conversion is independent of cytochrome P-450, making drug-drug and drug-diet interactions less likely. Dabigatran is predominantly excreted via a renal pathway. Dabigatran was evaluated in a large, open-label, randomized trial (RE-LY) in which it was compared with warfarin (goal international normalized ratio [INR] 2.0 to 3.0) in 18,113 patients with nonvalvular AF (3). Dabigatran was administered in fixed doses without laboratory monitoring of anticoagulation intensity. Eligible participants had at least 1 risk factor for stroke (previous stroke or transient ischemic attack or systemic embolism, left ventricular ejection fraction <40% or symptomatic heart failure [New York Heart Association class II or higher in the last 6 months], hypertension, age ≥75 years, or age 65 to 74 years with either diabetes mellitus or coronary artery disease). Exclusion criteria in RE-LY included a prosthetic heart valve or hemodynamically significant valvular heart disease, disabling or recent stroke, recent or pending surgery, recent or known bleeding disorders, uncontrolled hypertension, need for anticoagulation of disorders other than AF, planned ablation or surgery for AF, reversible causes of AF, severe renal dysfunction (creatinine clearance <30 mL/min), active liver disease, or pregnancy. Two doses of dabigatran (110 mg and 150 mg twice daily) were evaluated. The mean age of participants was 71 years, 63.6% were male, half had prior long-term therapy with vitamin K antagonists, and the mean CHADS2 (Congestive heart failure, Hypertension, Age, Diabetes, prior Stroke) risk prediction score was 2.1. The primary outcome was all stroke (ischemic or hemorrhagic) or systemic embolism; safety outcomes included bleeding, liver dysfunction, and other adverse events.
Results of the RE-LY trial were published in 2009 (3). Rates for the primary outcome of all stroke (ischemic or hemorrhagic) or systemic embolism were 1.71% per year in the warfarin group. Dabigatran etexilate, 150 mg twice daily, reduced the rate by 34% (to 1.11% per year; p<0.001 for superiority; RR: 0.65; 95% CI: 0.52 to 0.81), and at this dose there was no increase in major bleeding (3). Dabigatran etexilate, 110 mg twice daily, was also associated with a rate of stroke and systemic embolism (1.54% per year) that was noninferior to warfarin (p<0.001 for noninferiority) (RR with dabigatran 0.90; 95% CI: 0.74 to 1.10), and at this dose there was a 20% reduction in major bleeding risk compared with warfarin (p=0.003 for superiority). Rates of major bleeding were 3.57% per year for patients on warfarin, 2.87% per year for those on dabigatran 110 mg twice daily (p=0.003), and 3.32% per year for those on dabigatran 150 mg twice daily (p=0.32). In the warfarin group, INR values were within the target range 64.4% of the time (4).
In addition, the results showed other secondary benefits and adverse outcomes. For safety, both doses showed a reduction in life-threatening, intracranial, and total bleeding, including lower rates of intracerebral hemorrhage with both 150 mg and 110 mg twice-daily doses (from 0.38% per year in the warfarin group to 0.12% per year with dabigatran 110 mg twice daily [p<0.001] and 0.10% per year with dabigatran 150 mg twice daily [p<0.001]). Dyspepsia occurred more frequently with dabigatran (11.8% and 11.3% of patients in the low- [110 mg] and high- [150 mg] dose groups, respectively) compared to warfarin (5.8% of patients). Also, myocardial infarction was more frequent with dabigatran and occurred at rates of 0.82% (RR: 1.29; 95% CI: 0.96 to 1.75; p=0.09) and 0.81% (RR: 1.27; 95% CI: 0.94 to 1.71; p=0.12) with dabigatran, 110 mg and 150 mg twice daily, respectively, and 0.64% with warfarin (3,4). Increased (3) or decreased (5) rates of myocardial infarction have been reported with other oral thrombin inhibitors in different patient populations; however, the increase in myocardial infarction seen in RE-LY was not statistically significant in the dabigatran groups (4). In RE-LY, dabigatran did not cause hepatotoxicity (3). Drug discontinuation rates were slightly higher in the dabigatran groups compared with warfarin. There was no difference in mortality with dabigatran compared with warfarin. Both dabigatran doses appeared to be noninferior to warfarin with respect to the primary efficacy outcome of stroke or systemic embolism. In addition, the 150 mg twice-daily dose was superior to warfarin with respect to stroke or systemic embolism, and the 110 mg twice-daily dose was superior to warfarin with respect to major bleeding. There is no specific antidote for dabigatran, which has a half-life of 12 to 17 hours. Supportive therapy for severe hemorrhage may include transfusions of fresh frozen plasma, packed red blood cells, or surgical intervention if appropriate.
Because of the twice-daily dosing and greater risk of nonhemorrhagic side effects with dabigatran, patients already taking warfarin with excellent INR control may have little to gain by switching to dabigatran. Selection of patients with AF and at least 1 additional risk factor for stroke who could benefit from treatment with dabigatran as opposed to warfarin should consider individual clinical features, including the ability to comply with twice-daily dosing, availability of an anticoagulation management program to sustain routine monitoring of INR, patient preferences, cost, and other factors (6).
Dabigatran etexilate was approved by the FDA on October 19, 2010, for marketing in the United States for the prevention of stroke and systemic embolism in patients with nonvalvular AF. A dose of 150 mg twice daily was approved for patients with a creatinine clearance >30 mL/min, whereas in patients with severe renal insufficiency (creatinine clearance 15 to 30 mL/min) the approved dose is 75 mg twice daily, a dose currently marketed in the European Union but not evaluated in the RE-LY trial. There are no dosing recommendations for patients with creatinine clearance <15 mL/min or patients on dialysis. The 110 mg twice-daily dose used in the RE-LY trial did not receive FDA approval. The approval requires distribution of a medication guide with each prescription that details the risk of serious bleeding in patients receiving dabigatran in this open-label (or “unblinded”) trial (7). Dabigatran is the first new oral anticoagulant to become available for clinical use in >50 years.
American College of Cardiology Foundation
John C. Lewin, MD, Chief Executive Officer
Janet Wright, MD, FACC, Senior Vice President, Science and Quality
Charlene May, Senior Director, Science and Clinical Policy
Lisa Bradfield, CAE, Director, Science and Clinical Policy
Sue Keller, BSN, MPH, Senior Specialist, Evidence-Based Medicine
Erin A. Barrett, MPS, Senior Specialist, Science and Clinical Policy
Beth Denton, Specialist, Science and Clinical Policy
American Heart Association
Nancy Brown, Chief Executive Officer
Rose Marie Robertson, MD, FAHA, Chief Science Officer
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations
Mark D. Stewart, MPH, Science and Medicine Advisor, Office of Science Operations
↵⁎ ACCF/AHA Representative.
↵† HRS Representative.
↵‡ ACCF/AHA Task Force on Performance Measures Representative.
↵§ Recused from voting on Section 18.104.22.168.5, Recommendation for Use of Oral Direct Thrombin Inhibitor Anticoagulant Agents.
↵∥ ACCF/AHA Task Force on Practice Guidelines Liaison.
This document was approved by the American College of Cardiology Foundation Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, and the Heart Rhythm Society in January 2011.
The American College of Cardiology Foundation requests that this document be cited as follows: Wann LS, Curtis AB, Ellenbogen KA, Estes NAM 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, writing on behalf of the 2006 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:1330–7.
This article is copublished in Circulation and HeartRhythm.
Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), and the Heart Rhythm Society (www.hrsonline.org). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail .
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at firstname.lastname@example.org.
- American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Rhythm Society
- ↵ACCF/AHA Task Force on Practice Guidelines: Methodologies and Policies from the ACCF/AHA Task Force on Practice Guidelines. http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf http://circ.ahajournals.org/manual/. Last update July 20, 2010. Accessed January 3, 2011.
- Fuster V.,
- Ryden L.E.,
- Cannom D.S.,
- et al.
- ↵Dabigatran medication guide. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Pradaxa/Patient+Info/PradaxaMedGuide.pdf. Last update November 23, 2010. Accessed January 3, 2011.